Is DVAX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,177 people get DVAX articles and Market Currents by email alert.

Get email alerts on DVAX »

HEADLINES:

A Review Of Upcoming Catalysts For Kidney Disease Biotech Players In 2013
Tech Guru • Fri, May 24 • 1 Comment
Dynavax Reports First Quarter 2013 Financial Results

Marketwire (May 6, 2013)
Dynavax Names Eddie Gray as Chief Executive Officer and Member of the Board of Directors

Marketwire (Apr 30, 2013)
Dynavax: A Compelling Buy
Alexander Maxwell • Mon, Mar 25 • 15 Comments
Solving The R&D Investment Dilemma With Project Funding: Mark Kessel
Life Sciences Report • Sun, Mar 24 • 1 Comment
Bio Run-Ups: What To Expect In The Next Few Months
Alexander Maxwell • Fri, Mar 22 • 33 Comments
Dynavax Surprises: Announces Strategic Global Operations Hire
Theodore Cohen • Fri, Mar 22 • 11 Comments
Dynavax Appoints David Novack as Senior Vice President, Operations and Quality

Marketwire (Mar 21, 2013)
Catalyst Pharmaceutical And Dynavax Are Buys Now
BuySellShort • Fri, Mar 8 • 1 Comment
Biopharmaceutical Sector Spurs New Investment Opportunities
Cris Frangold • Sun, Mar 3 • 3 Comments
Dynavax Reports Fourth Quarter and Year End 2012 Financial Results

Marketwire (Mar 1, 2013)
Dynavax: A Takeover Target?
Theodore Cohen • Wed, Feb 27 • 22 Comments
FDA Rejection Knocks Dynavax Down, But Not Out
Brian L. Wilson • Tue, Feb 26 • 6 Comments
Dynavax Technologies: Key Issues To Consider
Biomed Group • Tue, Feb 26
Dynavax: The Path Forward
Theodore Cohen • Tue, Feb 26 • 31 Comments
Dynavax to Present at the Cowen and Company 33rd Annual Healthcare Conference

Marketwire (Feb 26, 2013)
VIX - Options Volatility And Market Sonar: Monday Recap
Erick McKitterick • Mon, Feb 25 • 6 Comments
Dynavax Technologies's CEO Discusses the Complete Response Letter from the FDA regarding BLA for HEPLISAV (Transcript)
Mon, Feb 25 • 2 Comments
Dynavax Receives FDA Complete Response Letter on HEPLISAV(TM) Biologic License Application

Marketwire (Feb 25, 2013)
Cramer's Mad Money - Beware Of Takeover Rumors (2/20/13)
SA Editor Miriam Metzinger • Thu, Feb 21 • 6 Comments

To learn more about Seeking Alpha Pro, click here.

Dynavax: A Compelling Buy
Alexander Maxwell • Mon, Mar 25 • 15 Comments
Dynavax Surprises: Announces Strategic Global Operations Hire
Theodore Cohen • Fri, Mar 22 • 11 Comments
Dynavax: A Takeover Target?
Theodore Cohen • Wed, Feb 27 • 22 Comments
FDA Rejection Knocks Dynavax Down, But Not Out
Brian L. Wilson • Tue, Feb 26 • 6 Comments
Dynavax Technologies: Key Issues To Consider
Biomed Group • Tue, Feb 26
Dynavax: The Path Forward
Theodore Cohen • Tue, Feb 26 • 31 Comments
William Blair Analysts Are Gaining Comfort Ahead Of Dynavax's Heplisav PDUFA
Ben Yoffe • Mon, Jan 14 • 13 Comments
Dynavax's Heplisav: Vaccinated Against Failure?
Jordan Pease • Wed, Jan 9 • 17 Comments
Dynavax Initiates New Phase I Trial For Lymphomas
Theodore Cohen • Tue, Dec 18, 2012 • 8 Comments
Why Dynavax's Heplisav Is Likely To Be Approved: Impact On Future Vaccine Development
Richard Daifuku • Wed, Nov 21, 2012 • 26 Comments
The Fall Of Another Promising Biotech - Dynavax Technologies
EnhydrisPECorp • Fri, Nov 16, 2012 • 8 Comments
Dynavax Gets Crushed After Advisory Committee Vote
Brian L. Wilson • Fri, Nov 16, 2012 • 7 Comments
Dynavax Crashes On Unexpected Panel Vote
Theodore Cohen • Fri, Nov 16, 2012 • 40 Comments
Dynavax Shares Jump On Release Of FDA Briefing Materials
Theodore Cohen • Tue, Nov 13, 2012 • 34 Comments
Dynavax Upcoming Binary Event: HBV Vaccine Under Review By FDA Advisory Panel
Bio Vantage • Mon, Nov 12, 2012 • 4 Comments
Despite Safety Concerns, Dynavax's Heplisav Should Receive FDA Approval
Beacon VP Investments • Tue, Nov 6, 2012 • 21 Comments
Analysts At William Blair Maintain Outperform On Dynavax Technologies
Ben Yoffe • Mon, Nov 5, 2012 • 1 Comment
Dynavax Advances Agonist For Asthma Into The Clinic
Theodore Cohen • Wed, Oct 31, 2012 • 4 Comments
85% Probability Of FDA Approval For Dynavax's Heplisav, Says Cowen's Senior Analyst
Ben Yoffe • Thu, Oct 25, 2012 • 10 Comments
Dynavax Shares Poised To Run Higher As Heplisav Approaches Important Catalysts
R.S. Analytics • Fri, Oct 12, 2012 • 7 Comments

A Review Of Upcoming Catalysts For Kidney Disease Biotech Players In 2013
Tech Guru • Fri, May 24 • 1 Comment
Solving The R&D Investment Dilemma With Project Funding: Mark Kessel
Life Sciences Report • Sun, Mar 24 • 1 Comment
Bio Run-Ups: What To Expect In The Next Few Months
Alexander Maxwell • Fri, Mar 22 • 33 Comments
Catalyst Pharmaceutical And Dynavax Are Buys Now
BuySellShort • Fri, Mar 8 • 1 Comment
Biopharmaceutical Sector Spurs New Investment Opportunities
Cris Frangold • Sun, Mar 3 • 3 Comments
VIX - Options Volatility And Market Sonar: Monday Recap
Erick McKitterick • Mon, Feb 25 • 6 Comments
Cramer's Mad Money - Beware Of Takeover Rumors (2/20/13)
SA Editor Miriam Metzinger • Thu, Feb 21 • 6 Comments
4 Small Cap Biopharmas With Near-Term Catalysts
Scott Matusow • Mon, Feb 11 • 22 Comments
Cramer's Lightning Round - Dynavax Is Coming Back (2/6/13)
SA Editor Miriam Metzinger • Thu, Feb 7 • 1 Comment
Predicting Biotech Stock Moves Based On Consensus Picks By Legendary Fund Managers
GuruFundPicks • Tue, Feb 5 • 3 Comments
5 Stocks Under $4 On Winning Streaks
Kapitall • Tue, Jan 15 • 5 Comments
Upcoming FDA Approval Decision Dates For Q1 2013
David Zanoni • Sun, Jan 13 • 13 Comments
Cramer's Lightning Round - Pfizer Is Fine (11/27/12)
SA Editor Miriam Metzinger • Wed, Nov 28, 2012 • 3 Comments
Biotech Weekend Recap: Short Week, Major Rally
Brian L. Wilson • Sun, Nov 25, 2012 • 10 Comments
Cramer's Mad Money - 7 Earnings To Watch In The Week Ahead (11/16/12)
SA Editor Miriam Metzinger • Mon, Nov 19, 2012 • 5 Comments
Biotech Weekend Recap: Frustration And Disasters
Brian L. Wilson • Sun, Nov 18, 2012 • 9 Comments
4 Rallying Hedge Fund Picks Trading Under $5
Kapitall • Fri, Nov 16, 2012 • 3 Comments
Promising Biotech Stocks With Upcoming FDA Catalysts
David Zanoni • Tue, Nov 13, 2012 • 3 Comments
VIX - Options Volatility Sonar: Monday Recap
Erick McKitterick • Tue, Nov 13, 2012 • 2 Comments
Biotech Catalyst Calendar - 4 Stocks To Watch In November
LifeSci Advisors • Wed, Nov 7, 2012 • 11 Comments

Dynavax Technologies's CEO Discusses the Complete Response Letter from the FDA regarding BLA for HEPLISAV (Transcript)
Mon, Feb 25 • 2 Comments
Dynavax Technologies Corporation Q4 2007 Earnings Call Transcript
Tue, Feb 19, 2008

Dynavax Reports First Quarter 2013 Financial Results

Marketwire (May 6, 2013)
Dynavax Names Eddie Gray as Chief Executive Officer and Member of the Board of Directors

Marketwire (Apr 30, 2013)
Dynavax Appoints David Novack as Senior Vice President, Operations and Quality

Marketwire (Mar 21, 2013)
Dynavax Reports Fourth Quarter and Year End 2012 Financial Results

Marketwire (Mar 1, 2013)
Dynavax to Present at the Cowen and Company 33rd Annual Healthcare Conference

Marketwire (Feb 26, 2013)
Dynavax Receives FDA Complete Response Letter on HEPLISAV(TM) Biologic License Application

Marketwire (Feb 25, 2013)
Lightning Round: Coinstar, Lockheed Martin & More

at CNBC.com (Feb 6, 2013)
Dynavax to Present at the 31st Annual J.P. Morgan Healthcare Conference

Marketwire (Dec 17, 2012)
Lightning Round: Abercrombie & Fitch, Research In Motion, & More

at CNBC.com (Nov 27, 2012)
Cramer's Calls on Omega Healthcare, InvenSense and More

at CNBC.com (Nov 16, 2012)
Midday Movers: OMX, BBY, FB & More

at CNBC.com (Nov 16, 2012)
Dynavax Announces FDA Advisory Committee Meeting Outcome for HEPLISAV(TM)

Marketwire (Nov 15, 2012)
Dynavax Reports Third Quarter 2012 Financial Results

Marketwire (Nov 1, 2012)
Dynavax to Initiate Phase 1 Studies for TLR-9 Agonist for Asthma

Marketwire (Oct 31, 2012)
Lightning Round: Ford, Sirius XM, Intel & More

at CNBC.com (Oct 16, 2012)
Dynavax Announces FDA Advisory Committee to Review HEPLISAV(TM)

Marketwire (Aug 28, 2012)
Dynavax Marketing Authorization Application for HEPLISAV(TM) Accepted for Review by European Medicines Agency

Marketwire (Aug 22, 2012)
Dynavax Appoints Christine Larson as Chief Financial Officer

Marketwire (Aug 13, 2012)
Dynavax Reports Second Quarter 2012 Financial Results

Marketwire (Aug 1, 2012)
Dynavax Submits HEPLISAV(TM) for EU Marketing Authorization

Marketwire (Jul 24, 2012)

DVAX vs. ETF Alternatives

Company Description

Dynavax Technologies Corporation (“Dynavax” or the “Company”), a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases. The Company’s lead product candidate is HEPLISAVTM, a Phase... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 6, 5:15 PM More on Dynavax (DVAX): Q1 misses on bottom line estimates as the company logs higher R&D and SG&A expenses and revenue declines slightly Y/Y. Total expenses rose by 21% over the prior year period, due primarily to the purchase of a Heplisav component as well as severance expenses, including non-cash stock-based compensation charges. Shares -1.7% AH. Comment! [Healthcare, Earnings, On the Move]
Monday, May 6, 5:13 PM Dynavax Technologies (DVAX): Q1 EPS loss of $0.11 misses by $0.01. Revenues of $2.1M (-14% Y/Y) in line. (PR). Shares -1.7% AH. Comment! [Healthcare, Earnings, Breaking News, On the Move]
Monday, March 4, 2:48 PM Dynavax (DVAX -7.6%) takes a hit today after the company reported a wider Q4 net loss late Friday of $20.1 million late Friday, or $0.11 per share, more than the $4.3 million loss the same quarter a year prior. Analysts anticipated a loss of $0.08 per share. Revenues also came up short at $1.8M, down from $11.4M for the prior year period, and well under the $6.9M analysts expected. Comment! [Healthcare, On the Move, Earnings]
Friday, March 1, 4:30 PM Dynavax Technologies (DVAX): Q4 EPS of -$0.11. Revenue of $1.8M. Shares -2% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Monday, February 25, 12:53 PM Midday top 10 gainers: ENMD +26%. OBCI +25%. GALT +19%. APPY +15%. NTWK +12%. BKS +12%. ZNGA +11%. HXM +10%. MGN +10%. CMGE +9%.
Midday top 10 losers: AFFY -86%. CEDC -55%. DVAX -33%. GGS -31%. GMXR -24%. TROV -17%. EMITF -16%. ESI -14%. FRO -14%. XRSC -13%. Comment! [On the Move]
Monday, February 25, 8:10 AM Dynavax Technologies (DVAX) -33% premarket after the FDA rejects its hepatitis B vaccine Heplisav, citing the need for additional safety data in healthy adults. DVAX says it's confident it can meet the request for more information, but it may also fast-track a refiling by first seeking approval for sick patients. 2 Comments [Healthcare, On the Move]
Monday, January 14, 2:32 PM Investors interested in the prospects of young biotech companies might want to take a look at this Seeking Alpha article. It's a list of the upcoming FDA approval decision dates for Q1 2013, and with many of these developing firms having a good portion of their businesses riding on FDA approval decisions for their newly developed drugs, the stocks are likely to be sensitive to any positive or negative news over the near term. Comment! [Healthcare, Quick Ideas]
Wednesday, January 2, 1:20 PM Dynavax Technologies (DVAX +3%) moves up with the overall market today, shrugging off a less-than-stellar initiation at JPMorgan with a Neutral rating. The firm cites certain regulatory risks associated with DVAX's hepatitis B vaccine Heplisav. The stock dropped 47% in November after the FDA panel gave its decision that the drug's safety data was inadequate. Heplisav is an adjuvant vaccine that regulators say might cause autoimmune diseases. Comment! [Healthcare, On the Move]
Wednesday, November 21, 2012, 3:05 PM Dynavax Technologies (DVAX +3%) gains today after hedge fund HealthCor Management acknowledged boosting its stake in the company to 9.18%, or 16.4M shares. This is up 105% from the 8M shares held at the end of the latest quarter ending September 30, 2012. 1 Comment [Healthcare, On the Move]
Friday, November 16, 2012, 12:45 PM Midday top 10 gainers: SWSH +30%. PENN +30%. SHF +30%. OMX +20%. PRAN +17%. CCBG +20%. ASCA +15%. SUMR +14%. KWK +14%. OSIS +12%. Midday top 10 Losers: DIAL -76%. SAB -51%. DVAX -47%. SCMR -24%. BORN -20%. VIAS -18%. GAIA -18%. SHLD -17%. SINA -15%. EDS -15%. 2 Comments
Friday, November 16, 2012, 9:10 AM Premarket gainers: PENN +33%. SHF +29%. SWSH +22%. OMX +17%. ASCA +17%. CLNT +15%. BYD +12%. STSI +11%. MGM +7%. OSIS +6%. LVS +6%. VRNG +6%. GMCR +5%. CALI +5%. FRO +5%.
Losers: DVAX -48%. SINA -7%. Comment! [On the Move]
Thursday, November 15, 2012, 5:12 PM Dynavax Technologies (DVAX) plummets over 60% in heavy volume after-hours following the stock's release from a trading halt. Earlier, the company announced that the FDA Vaccines Advisory Committee had voted 13-1 that Heplisav data adequately demonstrated immunogenicity, but the committee also voted 8-5 with one abstention that there was insufficient data to adequately support the safety of the drug. 2 Comments [Healthcare, On the Move]
Wednesday, November 14, 2012, 8:39 AM Dynavax (DVAX) is +3.6% premarket and building on yesterday's 13% gain after FDA staff said the company's Heplisav vaccine for hepatitis B worked as well after two doses as GSK's (GSK) Engerix-B vaccine after three doses. An FDA advisory panel is due to discuss whether to recommend approval for Heplisav tomorrow, while the agency is scheduled to make an authorization decision in February. Comment! [Healthcare, On the Move]
Monday, September 17, 2012, 9:10 AM Premarket gainers: IRIS +45%. GNOM +15%. ODP +10%. KTOS +9%. CPRX +9%. TSLA +8%. DVAX +7%. CTIC +6%.
Losers: THLD -23%. Comment! [On the Move]
Tuesday, May 8, 2012, 7:39 PM Dynavax Technologies (DVAX) says that CEO Dino Dina has announced plans to step aside and bring on an executive with more commercial drug company experience. Additionally, the company also announces a secondary offering of an undisclosed number of shares. Shares -11.2% AH. Comment! [Healthcare, On the Move]
Friday, September 16, 2011, 2:53 PM Dynavax (DVAX +7.5%) jumps after saying it will present at an upcoming conference additional immunogenicity data from its Phase 3 trial of its hepatitis vaccine HEPLISAV. Comment! [Healthcare, Top Stories]

nsahbti
$DVAX To me Dino sounded a bit lost and confused on the "Special Call". They don't understand the details yet.
Feb 25, 12:35 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

brianq91
$DVAX in for a rough day today...shares down 30%, hepilsav needs further eval
Feb 25, 10:22 AM
Reply (1)

• !Report Abuse
View all 1 replies
phemale60: I couldn't take the heat; have hands full w/$VVUS $ONCY so sold my $DVAX premarket .. took $700 loss. That should teach me - hopefully.
Feb 25, 11:08 AM
• !Report Abuse
Add a reply...

140 characters

nsahbti
$DVAX What is the cause for this 7.5% slider?
Feb 20, 11:02 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

sundate36
Block trade data for $DVAX today is interesting: http://bit.ly/VQwgAU
Jan 8, 11:25 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

sundate36
Somebody bought 5mln $DVAX shares today at the close...
12/21/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Demetri Mallios
$DVAX has enjoyed a nice bounce. I think the committee was a bit harsh on Hepislav.
11/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

smokeyRose
Wow just took a peek at DVAX! YGH!!! glad I didn't Buy
11/16/12
Reply (4)

• !Report Abuse
View all 4 replies
phemale60: If really interested, see comments after decision. Eye opening.
11/17/12
• !Report Abuse
smokeyRose: that's A Shame PH I Know The Feeling. went Down that road with $KERX Skirted out of a Bad one with $TZYM sold for $4 next Morning 98 Cents!
11/21/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/Utz3yp STOCKS FOR NOV 16TH: $GPS, $ADSK, $MRVL, $DVAX, $NUGT, $DUST
11/15/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jack Holland
See my Instablog on DVAX for an analysis of the evening's slaughter...
11/15/12
Reply (1)

• !Report Abuse
View all 1 replies
Noreika: Maybe a chance for a buy-in?
11/15/12
• !Report Abuse
Add a reply...

140 characters

Jack Holland
DVAX may drop a buck or two...get ready...if you have planned well, don't panic sell...let others do that...save some for Feb.
11/15/12
Reply (2)

• !Report Abuse
View all 2 replies
Droney: Wow...they didn't get it...bummer...
11/15/12
• !Report Abuse
Ghostrider1: So glad I took your advice and sold half yesterday. Hopefully it does'nt get hammered too bad.
11/15/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

brianq91
$DVAX in for a rough day today...shares down 30%, hepilsav needs further eval
Feb 25, 10:22 AM
Reply (1)

• !Report Abuse
View all 1 replies
phemale60: I couldn't take the heat; have hands full w/$VVUS $ONCY so sold my $DVAX premarket .. took $700 loss. That should teach me - hopefully.
Feb 25, 11:08 AM
• !Report Abuse
Add a reply...

140 characters

smokeyRose
Wow just took a peek at DVAX! YGH!!! glad I didn't Buy
11/16/12
Reply (4)

• !Report Abuse
View all 4 replies
phemale60: If really interested, see comments after decision. Eye opening.
11/17/12
• !Report Abuse
smokeyRose: that's A Shame PH I Know The Feeling. went Down that road with $KERX Skirted out of a Bad one with $TZYM sold for $4 next Morning 98 Cents!
11/21/12
• !Report Abuse
Add a reply...

140 characters

Jack Holland
DVAX looks positive so far....
11/13/12
Reply (4)

• !Report Abuse
View all 4 replies
1980XLS-2.0: Not now!
11/15/12
• !Report Abuse
Jack Holland: Depends on when you got in and when you got out.
11/19/12
• !Report Abuse
Add a reply...

140 characters

Jack Holland
Looks like the weak speculators are losing their courage this afternoon. Don't be a sucker and don't gamble 100% of your capital on DVAX
11/14/12
Reply (11)

• !Report Abuse
View all 11 replies
Jack Holland: By the way you didn't get screwed by FDA, the Advisory Panel is independent. The FDA was on your side apparently...
11/16/12
• !Report Abuse
phemale60: I saw my mistake after I posted it, but thanks. Love the artwork on your newspaper, BTW!
11/16/12
• !Report Abuse
Add a reply...

140 characters

phemale60
DVAX --- what's up? Must be promising for sure. Glad I held on but guess some profit taking to come in short term.
11/13/12
Reply (2)

• !Report Abuse
View all 2 replies
1980XLS-2.0: Bit more than profit taking, methinks
11/15/12
• !Report Abuse
phemale60: Hah! I freaked and sold half at $1.75 -- pitiful! Will hold awhile on chance FDA still approves 2/24/13. Possible! Just saw "Buy" from MLV
11/16/12
• !Report Abuse
Add a reply...

140 characters

Jack Holland
See my Instablog on DVAX for an analysis of the evening's slaughter...
11/15/12
Reply (1)

• !Report Abuse
View all 1 replies
Noreika: Maybe a chance for a buy-in?
11/15/12
• !Report Abuse
Add a reply...

140 characters

Jack Holland
DVAX maybe McDonald's instead of steak tonight...panel has too questions on safety..if this sells off...be careful selling into panic!
11/15/12
Reply (2)

• !Report Abuse
View all 2 replies
smokeyRose: Good luck my Friend. i was Going to Buy yesterday but didn't. Learning my way around the Bio-Pharm Minefield!
11/15/12
• !Report Abuse
Jack Holland: Look for a blog post later...
11/15/12
• !Report Abuse
Add a reply...

140 characters

Jack Holland
or..DVAX Trading most likely halted awaiting news...
11/15/12
Reply (11)

• !Report Abuse
View all 11 replies
JGWjr: FDA meeting's concluded. When will they start trading DVAX again?
11/15/12
• !Report Abuse
Jack Holland: Probably will trade in after hours market around 4:30 p.m.
11/15/12
• !Report Abuse
Add a reply...

140 characters

Jack Holland
DVAX may drop a buck or two...get ready...if you have planned well, don't panic sell...let others do that...save some for Feb.
11/15/12
Reply (2)

• !Report Abuse
View all 2 replies
Droney: Wow...they didn't get it...bummer...
11/15/12
• !Report Abuse
Ghostrider1: So glad I took your advice and sold half yesterday. Hopefully it does'nt get hammered too bad.
11/15/12
• !Report Abuse
Add a reply...

140 characters

smokeyRose
DVAX!! 4.85 up 0.67 16.03% Ahhhhh should I sell some losers and Buy this one?????? Hmmmmm
11/13/12
Reply (8)

• !Report Abuse
View all 8 replies
phemale60: smokeyRose: I've had DVAX on and off for past few years. It's time seems to have come. I know it's studies have been positive.
11/13/12
• !Report Abuse
phemale60: Hep B vaccine taken in two shots instead of three. Not a huge money maker I guess, but still valuable-worth the risk for me. Watch it close
11/13/12
• !Report Abuse
Add a reply...

140 characters

Jack Holland
DVAX Volume at a mind blowing 6,068,435 Shares up from three month avg. of 1,944,220...welcome to Vegas baby!
11/12/12
Reply (3)

• !Report Abuse
View all 3 replies
GVT: Any news on FDA panel notes?
11/13/12
• !Report Abuse
Jack Holland: Go to my blog on DVAX
11/13/12
• !Report Abuse
Add a reply...

140 characters

Jack Holland
DVAX, hang on for 11/15 news, don't be a sucker and get flushed out by market maker. Watch The Pit on Netflix. Stocks can trade the same..
11/2/12
Reply (1)

• !Report Abuse
View all 1 replies
rjackOPTIONHO: in it to win it
11/3/12
• !Report Abuse
Add a reply...

140 characters

jtank
DVAX has been dropping this week, but i'm buying more. It's got too much potential to pass up.
10/19/12
Reply (2)

• !Report Abuse
View all 2 replies
zack54: There can't be anything good when a director sells 6m shares before a supposedly favorable outcome in november can there?
10/22/12
• !Report Abuse
jtank: well, maybe they're just trying to lock in some profits from the runup... only time will tell.
10/22/12
• !Report Abuse
Add a reply...

140 characters

tsc99999
DVAX ,Wow, huge drop today, what happened?
10/16/12
Reply (1)

• !Report Abuse
View all 1 replies
phemale60: Cramer gave it a plug last night so hope that helps!
10/17/12
• !Report Abuse
Add a reply...

140 characters

R.S. Analytics
DVAX...November 14 FDA Advisory Panel on Hepsilav. Good time to jump on board right now for the run-up.
10/10/12
Reply (1)

• !Report Abuse
View all 1 replies
Droney: Just did a little DD on this one and I like. Good place to put my SRPT profits. ;) Thx for the tip!
10/11/12
• !Report Abuse
Add a reply...

140 characters

DVAX Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation